Background Ranolazine, a piperazine derivative with anti‐ischemic effects, reduces the
frequency of angina and improves exercise performance in patients with chronic angina …

Objectives: We aimed to evaluate the efficacy and safety of ranolazine in a larger and more
diverse group of patients with angina than previously studied. Background: Ranolazine is an …

ContextRanolazine is a novel antianginal agent that reduces ischemia in patients with
chronic angina but has not been studied in patients with acute coronary syndromes (ACS) …

Introduction. Despite a successful percutaneous coronary intervention (PCI), several studies
reported that the recurrence of angina after revascularization, even complete, is a …

Objectives: The primary objective of the Monotherapy Assessment of Ranolazine In Stable
Angina (MARISA) trial was to determine the dose-response relationship of ranolazine, a …

Traditional anti-anginal agents such as β-blockers and nitrates improve symptoms of cardiac
ischemia by affecting either blood pressure or heart rates. Despite aggressive therapy, many …

ContextMany patients with chronic angina experience anginal episodes despite
revascularization and antianginal medications. In a previous trial, antianginal monotherapy …

The optimal management of coronary artery disease is based on achieving two parallel
objectives: 1) prevention of major cardiovascular events, and 2) resolution of symptoms …

Background Incomplete revascularisation is common after percutaneous coronary
intervention and is associated with increased mortality and adverse cardiovascular events …

Objectives: The purpose of this explanatory analysis was to investigate the relationship
between ST-segment depression and the rate-pressure product (RPP) during exercise to …